+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cerebral Palsy - Market Insight, Epidemiology and Market Forecast 2030

  • ID: 5387737
  • Report
  • July 2021
  • Region: Global
  • 158 pages
  • DelveInsight

FEATURED COMPANIES

  • Abbvie
  • Ipsen
  • Merz Pharmaceuticals
  • Supernus Pharmaceuticals
  • Teva Pharmaceuticals
  • MORE
This ‘Cerebral Palsy - Market Insights, Epidemiology, and Market Forecast - 2030' report delivers an in-depth understanding of cerebral palsy, historical and forecasted epidemiology as well as cerebral palsy market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Cerebral Palsy market report provides current treatment practices, emerging drugs, cerebral palsy market share of the individual therapies, current and forecasted cerebral palsy market size from 2018 to 2030 segmented by seven major markets. The Report also covers current cerebral palsy treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2018-2030

Cerebral Palsy: Disease Understanding and Treatment Algorithm

Cerebral Palsy Overview

A cerebral palsy is a group of disorders that affect movement and muscle tone or posture. It is caused by damage that occurs to the immature brain as it develops, most often before birth. This condition can cause problems with posture, gait (manner of walking), muscle tone, and coordination of movement. Depending on how the condition is managed, motor skills can improve or worsen over time. The specific forms of cerebral palsy are determined by the extent, type, and location of a child's abnormalities. The types include spastic cerebral palsy, dyskinetic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy.

The most common type of cerebral palsy is spastic cerebral palsy. People with spastic cerebral palsy have increased muscle tone, meaning their muscles are stiff, and, as a result, their movements can be awkward. Moreover, dyskinetic cerebral palsy causes problems in controlling the movement of hands, arms, feet, and legs, making it difficult to sit and walk. The movements are uncontrollable and can be slow and writhing or rapid and jerky. Ataxic cerebral palsy is the rarest form and predominately impairs balance and coordination. These patients walk with a wide-based gait and have intentional tremors.

Mixed types of cerebral palsy refer to symptoms that do not correspond to any single type of cerebral palsy but are a mix of types. Some people have symptoms of more than one type of cerebral palsy. The symptoms of cerebral palsy vary from person to person. A person with a mild condition, might walk a little awkwardly but might not need any special help. A person with severe cerebral palsy might need to use special equipment to walk or might not be able to walk at all and might need lifelong care. Cerebral palsy does not get worse over time, though the exact symptoms can change over a person's lifetime.

The majority of children have congenital cerebral palsy, that is, they were born with it. However, a small number of children have acquired cerebral palsy, which means the disorder begins after birth. Some causes of acquired cerebral palsy include brain damage in the first few months or years of life, brain infections such as bacterial meningitis or viral encephalitis, problems with blood flow to the brain, or head injury from a motor vehicle accident, a fall, or child abuse.

Cerebral Palsy Diagnosis

The testing strategy is based on the clinical picture, the pattern of development of symptoms, family history, and other factors influencing the probability of specific diagnoses. Surveillance for associated disabilities such as hearing and vision impairment, seizures, perception problems with touch or pain, and cognitive dysfunction can help complete the clinical assessment and determine the diagnosis. Several assessment instruments are available to quantify and monitor developmental milestones and skills and to assess the quality of life of patients and their caregivers.

Cerebral palsy is usually diagnosed anywhere between 18 months and 5 years of age. A cerebral palsy diagnosis is made using imaging tests to observe any form of brain damage. The imaging tests include cranial ultrasounds, computed tomography scans (CT), electroencephalograms (EEG), and magnetic resonance imaging (MRI).

Cerebral Palsy Treatment

The goal of managing cerebral palsy is not to cure or achieve normalcy but to increase functionality, improve capabilities, and sustain health in terms of locomotion, cognitive development, social interaction, and independence. Several different methods are used to treat cerebral palsy symptoms, but the best clinical outcomes result from early, intensive management. Optimal treatment in children requires a team approach, and cerebral palsy babies may require early medical intervention to help brain development. Medication may be used to treat some symptoms of cerebral palsy, including involuntary movement, seizures, and spasticity. Common classes of medications for children with cerebral palsy include anticholinergics, anticonvulsants, antidepressants, anti-inflammatories, baclofen, and benzodiazepines.

Moreover, surgery may be recommended for children with severe mobility and muscle issues. Surgery can correct or improve issues with movement in the legs, ankles, feet, hips, wrists, and arms. Muscles, tendons, bones, and nerves are operated on to improve movement in these areas of the body. In addition, specialized assistive devices can help individuals with cerebral palsy that experienced issues with communication, hearing, and vision

Cerebral Palsy Epidemiology

The Cerebral Palsy epidemiology division provides insights about the historical and current Cerebral Palsy patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

In the year 2020, the total prevalent case of cerebral palsy was 1.8 million cases in the 7MM which are expected to grow during the study period, i.e., 2018-2030.

The disease epidemiology covered in the report provides historical as well as forecasted cerebral palsy epidemiology [segmented as Total Prevalent Cases of Cerebral Palsy, Total Diagnosed Cases of Cerebral Palsy, Total Type-specific cases of Cerebral Palsy, and Treated cases of Cerebral Palsy] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Cerebral Palsy Epidemiology

Estimates show that the highest cases of cerebral palsy in the 7MM were in the United States, followed by Japan, the United Kingdom, Germany, France, Spain, and Italy in 2020.
  • In the United States, the total number of prevalent cases of cerebral palsy was approximately 1 million cases in the year 2020 which are expected to grow during the study period, i.e., 2018-2030.
  • In the year 2020, the total prevalent cases of cerebral palsy were approximately 0.7 million cases in EU-5 which are expected to grow during the study period, i.e., 2018-2030.
  • In Japan, the total number of prevalent cases of cerebral palsy was 0.2 million cases in the year 2020 which are expected to grow during the study period, i.e., 2018-2030.
Cerebral Palsy Drug Chapters

The drug chapter segment of the Cerebral Palsy report encloses the detailed analysis of cerebral palsy marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the cerebral palsy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Cerebral Palsy Approved Drugs

Dysport/abobotulinumtoxinA (Ipsen)

Dysport is an injectable form of a botulinum neurotoxin type A product, which is a substance derived from Clostridium bacteria producing botulinum toxin type A (BoNT-A) that inhibits the effective transmission of nerve impulses and thereby reduces muscular contractions. It is supplied as a lyophilized powder. Dysport inhibits the release of the neurotransmitter acetylcholine from peripheral cholinergic nerve endings. Toxin activity occurs in the following sequence Toxin heavy chain mediated binding to specific surface receptors on nerve endings, internalization of the toxin by receptor-mediated endocytosis, pH-induced translocation of the toxin light chain to the cell cytosol, and cleavage of SNAP25 leading to intracellular blockade of neurotransmitter exocytosis into the neuromuscular junction.

In July 2020, the US FDA approved the expanded use of Dysport (abobotulinumtoxinA) in pediatric patients. Therefore, Dysport is now FDA-approved to treat both upper and lower limb spasticity in pediatric patients 2 years of age and older, including spasticity caused by cerebral palsy.

Botox/Onabotulinum toxin A (Abbvie)

OnabotulinumtoxinA is a sterile, vacuum-dried purified botulinum toxin type A, produced from the fermentation of Hall strain Clostridium botulinum type A and intended for intramuscular, intradetrusor, and intradermal use. It is purified from the culture solution by dialysis and a series of acid precipitations to a complex consisting of the neurotoxin and several accessory proteins. Botox is one of the most widely researched medications globally, with a proven history as a therapeutic agent. It is an acetylcholine release inhibitor and a neuromuscular blocking agent. Unlike oral treatments, it is administered directly to specific muscles, helping reduce the stiffness and tightness caused by spasticity.

In July 2020, the US FDA had approved a supplemental Biologics License Application (sBLA) that supported the expanded use of Botox to treat spasticity in pediatric patients 2 years and older, including those with lower limb spasticity caused by cerebral palsy.

Note: Detailed Current therapies assessment will be provided in the full report of Cerebral Palsy

Cerebral Palsy Emerging Drugs

Xeomin/Incobotulinum toxin A (Merz Pharmaceuticals)

Xeomin (incobotulinumtoxinA) is a purified neurotoxin type A (150kD) free from complexing proteins that prevent the release of the neurotransmitter acetylcholine from nerve endings at muscles and salivary glands. Botulinum neurotoxin (BoNT) type A is an effective and well-tolerated treatment option for focal spasticity in children with cerebral palsy. IncobotulinumtoxinA (Xeomin) is a BoNT type A formulation that is free from complexing proteins and therefore has a high specific neurologic activity. It inhibits acetylcholine release from nerve terminals at the motor endplate, preventing synaptic transmission.

This causes a temporary reduction in the muscular activity of injected muscles and reduces the pain associated with muscular hyperactivity. Focal injection means that only the symptomatic muscles are treated, with a duration of paresis of around 2-3 months, thereby limiting systemic side effects. Reduction of spasticity after BoNT type A injection should open a therapeutic window for other interventions in cerebral palsy by preventing contracture formation and enhancing both motor ability and functional skills.

Austedo/Deutetrabenazine (Teva Pharmaceuticals)

Austedo is considered a vesicular monoamine transporter 2 (VMAT2) inhibitor. It reversibly modifies dopamine, serotonin, norepinephrine, and histamine, which are neurotransmitters in the brain. The vesicular monoamine transporter type 2 (VMAT2) inhibitors are agents that cause a depletion of neuroactive peptides such as dopamine in nerve terminals. The VMAT2 inhibitors have not been associated with serum enzyme elevations during therapy or linked to instances of clinically apparent liver injury, but they have had limited general clinical use. The use of deutetrabenazine to treat dyskinesia in cerebral palsy is investigational and not currently approved by the US FDA or any other country's regulatory agency for this use.

Myobloc/RimabotulinumtoxinB (Supernus Pharmaceuticals)

RimabotulinumtoxinB (Myobloc), also called botulinum toxin type B, is made from the bacteria that causes botulism. Botulinum toxin blocks nerve activity in the muscles, causing a temporary reduction in muscle activity. RimabotulinumtoxinB is an acetylcholine release inhibitor. Myobloc blocks cholinergic transmission at the neuromuscular and salivary neuroglandular junction by inhibiting the release of acetylcholine from peripheral cholinergic nerve terminals. This inhibition occurs according to the following sequence: neurotoxin binding to cholinergic nerve terminals, internalization of the neurotoxin into the nerve terminal, translocation of the light-chain part of the molecule into the cytosol of the nerve terminal, and enzymatic cleavage of synaptic Vesicle Associated Membrane Protein (VAMP, also known as synaptobrevin), a presynaptic target protein essential for the release of acetylcholine.

UDI-001 (Rohto Pharmaceutical)

UDI-001 is Rohto Pharmaceuticals' novel candidate for a neurological disorder such as Cerebral Palsy. UDI-001 consists of umbilical cord-derived mesenchymal stromal cells (UC-MSCs). Mesenchymal stem cells have advantages such as high anti-inflammatory effects and low risk of canceration, and cell therapeutic agents using these cells are being developed worldwide. On the other hand, the mechanism of action has not been fully elucidated. It is difficult to clarify which function of mesenchymal stem cells exerts an effect on which target disease, and to understand the mechanism of action for each target disease. Human adipose-derived mesenchymal stem cells (hAd-MSC) have been the subject of many investigations and have attracted significant attention to their potential therapeutic applications. Ad-MSC possesses pluripotential properties capable of differentiating into several types of cells: adipocyte, myocyte, chondrocyte, and osteocyte.

Note: Detailed emerging therapies assessment will be provided in the final report.

Cerebral Palsy Market Outlook

Cerebral Palsy is the name for a group of lifelong conditions that affect movement and coordination. It is caused by a problem with the brain that develops before, during, or soon after birth caused by brain damage during the first 3-to-5 years of a child's life. Brain damage also can lead to other issues, like sight, hearing, and learning problems. Cerebral palsy affects muscle tone, movement, and motor skills. It hinders the body's ability to move in a coordinated and purposeful way. It also can affect other body functions that involve motor skills and muscles, like breathing, bladder and bowel control, eating, and talking.

Some patients have a lot of trouble with movement or learning, while others do not. It depends on how much the brain was damaged. For example, the damage can be partial, affecting only the part of the brain that controls walking.

Currently, there is no cure for cerebral palsy. But resources and therapies can help children grow and develop to their greatest potential. Pharmacological therapies can help pediatric patients who have a lot of muscle pain and stiffness. They can take medicine by mouth or get it through a pump (the baclofen pump) placed under the skin. Surgery can help fix dislocated hips and scoliosis (curved spine), which are common in pediatric patients with cerebral palsy, and leg braces can also help with walking. Also, eating diets high in calcium, vitamin D, and phosphorus can help improve bone health.

Anticholinergic medications are used to treat uncontrolled movements such as tremors, spasticity, and drooling. Anticonvulsants, which reduce excessive brain stimulation to prevent seizure activity. Antidepressants are often prescribed to those with cerebral palsy to help treat depression, anxiety, and seizures (in certain instances). Muscle relaxants are often the first line of treatment for treating spasticity in many cases, as the medications are non-invasive and fairly common. Anti-inflammatory medications decrease pain, which can be a significant part of hypoxic-ischemic encephalopathy-related cerebral palsy.

Major therapies currently approved in the 7MM include Dysport (abobotulinumtoxinA) and Botox (onabotulinumtoxinA), among others.

At present, some companies have initiated clinical trials that investigate new treatment options. Key players such as Merz Pharmaceuticals (Xeomin), Teva Pharmaceuticals (Austedo), Supernus Pharmaceuticals (Myobloc), Rohto Pharmaceutical (UDI-001), and several others are investigating their candidates for the management of cerebral palsy in the 7MM.

Key Findings

The Cerebral Palsy market size in the 7MM is expected to change during the study period 2018-2030. The therapeutic market of Cerebral Palsy in the seven major markets is expected to increase during the study period (2018-2030) with a CAGR of 7.4%. According to the estimates, the highest market size of Cerebral Palsy is found in the United States followed by Japan.

The United States Market Outlook

The total market size of Cerebral Palsy therapies in the United States is expected to increase with a CAGR of 8.6% in the study period (2018-2030).

EU-5 Countries: Market Outlook

The total market size of Cerebral Palsy therapies in EU-5 countries is expected to increase with a CAGR of 4.8% in the study period (2018-2030).

Japan Market Outlook

The total market size of Cerebral Palsy therapies in Japan is expected to increase with a CAGR of 7.1% in the study period (2018-2030).

Cerebral Palsy Pipeline Development Activities

The drugs which are in pipeline include:
1. Xeomin/Incobotulinum toxin A (Merz Pharmaceuticals)
2. Austedo/Deutetrabenazine (Teva Pharmaceuticals)
3. Myobloc/RimabotulinumtoxinB (Supernus Pharmaceuticals)
4. UDI-001 (Rohto Pharmaceutical)
Note: Detailed emerging therapies assessment will be provided in the final report.

Analyst Commentary
  • The goal of management of cerebral palsy is not to cure or to achieve normalcy but to increase functionality, improve capabilities, and sustain health in terms of locomotion, cognitive development, social interaction, and independence. Treatment programs encompass physical and behavioral therapy, pharmacologic and surgical treatments, mechanical aids, and management of associated medical conditions. In physical, occupational, speech, and behavioral therapies, the goals include enhancing patient and caregiver interactions while providing family support.
  • If compared to all the emerging therapies Xeomin (Incobotulinum toxin A) and Myobloc (RimabotulinumtoxinB), will be going to have a major influence on the market size of Cerebral Palsy in the 7MM.
  • Still, there is a high unmet need for the current therapies for the treatment of Cerebral Palsy. Cerebral palsy cannot be cured, but treatment often improves a child's capabilities. Many children live their near-normal adult lives if their disabilities are properly managed. The challenges of management of cerebral palsy begin from diagnosis to the provision of care long after diagnosis. In its management, early diagnosis is important because the initial treatment is useful for the patient to gain control over normal activities.
Access and Reimbursement Scenario in Cerebral Palsy Therapies

In the United States, many children with cerebral palsy obtain health care coverage through managed Medicaid, but little is known about the current demographics or management of this high-need, complex population. Medicaid managed care provides health benefits and services through contracted agreements between state Medicaid plans and managed care organizations. These contracts are intended to reduce Medicaid program costs and better manage the utilization of health services. This analysis aimed to investigate Medicaid-managed care administrative claims data to develop population-level information about the prevalence of cerebral palsy and its management patterns and costs.

Pulgar et al. (2019) analyzed a study a proprietary database of managed Medicaid with coverage from 15 states, encompassing an average annual enrollment of 5.3 million individuals throughout 2013-2015. As per this study, average annualized Medicaid costs were more than 15 times higher for children with CP than the overall Medicaid population (USD 22,383 for children with CP vs. USD 1,358 for children in the Medicaid population). For children with CP, costs were mostly related to medical services (59.8%) and home health/long-term care/hospice care (29.1%). In addition, pharmacy costs accounted for 11.1% of spend.

In France, HAS has given favorable opinion for reimbursement in the local symptomatic treatment of spasticity of the upper limbs in children 2 years of age or older. SMR- Substantial; The clinical benefit of Dysport 300 and 500 SPEYWOOD UNITS powder for solution for injection is substantial in the local symptomatic treatment of spasticity of the upper limbs in children two years of age or older. ASMR- no clinical added value; demonstration of a dose-effect of Dysport on reduction of muscle tone 6 weeks after intramuscular injection in patients aged 2-17 years with cerebral palsy, mostly treated by physiotherapy or occupational therapy.

Moreover, the National Database of Health Insurance Claims and Specific Health Checkup of Japan was developed by the Japanese government to cover all health insurance schemes. For decades, Japan has had universal health coverage through its employee- and community-based social health insurance, covering the entire population. The database archives almost all information, including disease diagnoses listed in the claims, which makes it possible to follow uncommon diseases such as cerebral palsy and improve the count of disease cases by overcoming underestimating from the Patient Survey.

Note: Detailed HTA assessment will be provided in the final report.

KOL-Views

To keep up with current market trends, we take KOLs and SME's opinion working in the Cerebral Palsy domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Cerebral Palsy market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs Competitive and Market Intelligence analysis of the Cerebral Palsy Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
  • The report covers the descriptive overview of cerebral palsy, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
  • Comprehensive insight has been provided into the cerebral palsy epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for cerebral palsy is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the cerebral palsy market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global cerebral palsy market.
Report Highlights
  • In the coming years, the cerebral palsy market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Cerebral Palsy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for cerebral palsy. The launch of emerging therapies will significantly impact the cerebral palsy market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for cerebral palsy.
  • The in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Cerebral Palsy Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Cerebral Palsy Pipeline Analysis
  • Cerebral Palsy Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Cerebral Palsy Report Key Strengths
  • 10 Years Forecast
  • 7MM Coverage
  • Cerebral Palsy Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake
Cerebral Palsy Report Assessment
  • SWOT Analysis
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Conjoint Analysis
  • Market Attractiveness
  • Market Drivers and Barriers
Key Questions Answered

Market Insights:
  • What was the Cerebral Palsy Market share (%) distribution in 2018 and how it would look like in 2030?
  • What would be the Cerebral Palsy total market size as well as market size by therapies across the 7MM during the study period (2018-2030)?
  • What are the key findings of the market across the 7MM and which country will have the largest Cerebral Palsy market size during the study period (2018-2030)?
  • At what CAGR, the Cerebral Palsy market is expected to grow in the 7MM during the study period (2018-2030)?
  • What would be the Cerebral Palsy market outlook across the 7MM during the study period (2018-2030)?
  • What would be the Cerebral Palsy market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
  • Cerebral Palsy patient types/pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
  • How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration, and frequencies based on their clinical trial results?
  • Among the emerging therapies, what are the potential therapies which are expected to disrupt the Cerebral Palsy market?
Epidemiology Insights:
  • What are the disease risks, burdens, and unmet needs of Cerebral Palsy?
  • What is the historical Cerebral Palsy patient pool in the seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What would be the forecasted patient pool of Cerebral Palsy in the 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Cerebral Palsy?
  • Out of all the 7MM countries, which country would have the highest prevalent population of Cerebral Palsy during the study period (2018-2030)?
  • At what CAGR the population is expected to grow in the 7MM during the study period (2018-2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Cerebral Palsy?
Current Treatment Scenario and Emerging Therapies:
  • What are the current options for the treatment of Cerebral Palsy?
  • What are the current treatment guidelines for the treatment of Cerebral Palsy in the US, Europe, and Japan?
  • How many companies are developing therapies for the treatment of Cerebral Palsy?
  • How many therapies are developed by each company for the treatment of Cerebral Palsy?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Cerebral Palsy?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cerebral Palsy therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Cerebral Palsy and their status?
  • What are the key designations that have been granted for the emerging therapies for Cerebral Palsy?
  • What is the global historical and forecasted market of Cerebral Palsy?
Reasons to Buy
  • The report will help in developing business strategies by understanding trends shaping and driving the Cerebral Palsy market.
  • To understand the future market competition in the Cerebral Palsy market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Cerebral Palsy in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Cerebral Palsy market.
  • To understand the future market competition in the Cerebral Palsy market.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbvie
  • Ipsen
  • Merz Pharmaceuticals
  • Supernus Pharmaceuticals
  • Teva Pharmaceuticals
  • MORE
1. Key Insights

2. Report Introduction

3. Cerebral Palsy Market Overview at a Glance
3.1. Market Share (%) Distribution of Cerebral Palsy in 2018
3.2. Market Share (%) Distribution of Cerebral Palsy in 2030

4. Executive Summary of Cerebral Palsy
4.1. Key Events

5. Epidemiology and Market Methodology

6. Disease Background and Overview
6.1. Introduction
6.2. Types of Cerebral Palsy
6.3. Classification System of Cerebral Palsy
6.4. Signs and Symptoms of Cerebral Palsy
6.5. Risk Factors and Causes of Cerebral Palsy
6.6. Pathophysiology of Cerebral Palsy
6.7. Complications of Cerebral Palsy

7. Diagnosis of Cerebral Palsy
7.1. Diagnostic Algorithm
7.2. Screening of Newborns
7.3. Observational Diagnosis
7.4. Imaging Tests
7.5. Genetic Testing
7.6. Differential Diagnosis

8. Diagnostic Guidelines of Cerebral Palsy
8.1. National Institute for Health and Care Excellence (NICE) assessment guidelines in under 25s
8.2. Diagnostic Assessment of the Child With Cerebral Palsy - American Academy of Neurology and the Practice Committee of the Child Neurology Society

9. Current Treatment Practices: Cerebral Palsy
9.1. Treatment Algorithm of Cerebral Palsy
9.2. Drug Therapies
9.2.1. Anticholinergics
9.2.2. Anticonvulsants
9.2.3. Antidepressants
9.2.4. Antispastics
9.2.5. Anti-inflammatories
9.3. Surgery
9.4. Other treatment options

10. Treatment and Management Guidelines of Cerebral Palsy
10.1. NICE Treatment Guidelines in Adults With Cerebral Palsy
10.2. Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy - American Academy of Neurology and the Practice Committee of the Child Neurology Society
10.3. American Family Physician - Treatment guidelines

11. Epidemiology and Patient Population
11.1. Key Findings
11.2. Epidemiology of Cerebral Palsy
11.3. Epidemiology Scenario
11.3.1. Total Prevalent Cases of Cerebral Palsy
11.3.2. Total Diagnosed Cases of Cerebral Palsy
11.3.3. Total Type-specific Cases of Cerebral Palsy

12. Patient Journey

13. Key Endpoints in Cerebral Palsy Clinical Trials

14. Marketed Drugs
14.1. Dysport (abobotulinumtoxinA): Ipsen
14.1.1. Drug Description
14.1.2. Regulatory Milestones
14.1.3. Other Developmental Activities
14.1.4. Pivotal Clinical Trial
14.2. Botox (Onabotulinum toxin A): Abbvie
14.2.1. Drug Description
14.2.2. Regulatory Milestones
14.2.3. Other Developmental Activities
14.2.4. Pivotal Clinical Trial

15. Emerging Therapies
15.1. Xeomin (Incobotulinum toxin A): Merz Pharmaceuticals
15.1.1. Product Description
15.1.2. Other Developmental Activities
15.1.3. Clinical Development
15.1.4. Safety and Efficacy
15.2. Austedo (Deutetrabenazine; TEV50717): Teva Pharmaceuticals
15.2.1. Product Description
15.2.2. Other Developmental Activities
15.2.3. Clinical Development
15.3. Myobloc (RimabotulinumtoxinB): Supernus Pharmaceuticals
15.3.1. Product Description
15.3.2. Other Developmental Activities
15.3.3. Clinical Development
15.3.4. Safety and Efficacy
15.4. UDI-001: Rohto Pharmaceutical
15.4.1. Product Description
15.4.2. Clinical Development

16. Cerebral Palsy: 7 Major Market Analysis
16.1. Key Findings
16.2. Market Outlook
16.3. Market Size of Cerebral Palsy
16.3.1. Total Market Size of Cerebral Palsy
16.3.2. Market Size of Cerebral Palsy by Therapies

17. Market Access and Reimbursement
17.1. Key HTA decisions for Cerebral Palsy
17.2. Reimbursement
17.2.1. Assistance Programs
17.3. Patient Access Programs

18. KOL Views

19. Market Drivers

20. Market Barriers

21. SWOT Analysis

22. Unmet Needs

23. Appendix
23.1. Bibliography
23.2. Report Methodology

24. Publisher Capabilities

25. Disclaimer

26. About the Publisher

List of Tables
Table 1: Summary of Cerebral Palsy, Market, Epidemiology, and Key Events (2018-2030)
Table 2: Classification Based on Gross Motor Function Classification System
Table 3: Independent Risk Factors FOR Cerebral Palsy
Table 4: Total Prevalent Cases of Cerebral Palsy (in Thousands) (2018-2030)
Table 5: Total Diagnosed Cases of Cerebral Palsy (in Thousands) (2018-2030)
Table 6: Total Type-specific Cases of Cerebral Palsy (in Thousands) (2018-2030)
Table 7: Modified Ashworth Scale (MAS) Score
Table 8: Dysport Dosing by Muscle for Upper Limb Spasticity in Pediatric Patients
Table 9: Dysport Dosing by Muscle for Lower Limb Spasticity in Pediatric Patients
Table 10: Botox Dosing by Muscle for Pediatric Upper Limb Spasticity
Table 11: Botox Dosing by Muscle for Pediatric Lower Limb Spasticity
Table 12: Xeomin (Incobotulinum toxin A), Clinical Trial Description, 2021
Table 13: Austedo (Deutetrabenazine; TEV-50717), Clinical Trial Description, 2021
Table 14: Myobloc (RimabotulinumtoxinB), Clinical Trial Description, 2021
Table 15: UDI-001, Clinical Trial Description, 2021
Table 16: 7MM Market Size of Cerebral Palsy in USD Million (2018-2030)
Table 17: 7MM Market Size of Cerebral Palsy by Therapies in USD Million (2018-2030)
Table 18: Key HTA Decisions

List of Figures
Figure 1: Epidemiology and Market Methodology
Figure 2: Types of Cerebral Palsy
Figure 3: Signs and Symptoms
Figure 4: Causes and Risk Factors of Cerebral Palsy
Figure 5: Casual Factors of Cerebral Palsy Between 20 Weeks of Gestation Period
Figure 6: Main sites and Types of Genetic Variation in Cerebral Palsy
Figure 7: Diagnostic Algorithm
Figure 8: Cranial Ultrasound
Figure 9: Treatment Algorithm
Figure 10: Total Prevalent Cases of Cerebral Palsy in the 7MM (2018-2030)
Figure 11: Total Diagnosed Cases of Cerebral Palsy in the 7MM (2018-2030)
Figure 12: Total Type-specific Cases of Cerebral Palsy in the 7MM (2018-2030)
Figure 13: Botulinum Neurotoxin
Figure 14: Market Size of Cerebral Palsy in the 7MM, USD Million (2018-2030)
Figure 15: 7MM Market Size of Cerebral Palsy by Therapies in USD Million (2018-2030)
Note: Product cover images may vary from those shown
  • Ipsen
  • Abbvie
  • Merz Pharmaceuticals
  • Teva Pharmaceuticals
  • Supernus Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll